Image by storyset on FreepikBritish investment firm SV Health Investors has secured US$269m for its second fund, Dementia Discovery Fund, or DDF-2. The capital will be used to invest in companies developing or enabling novel therapeutics for dementia.
Tag Archive for: investment
BioSpringBioSpring GmbH has broken found for one of the world’s largest production facilities for pharmaceutical nucleic acid-based therapeutics. The new high-tech plant will significantly expand the company’s manufacturing capacity for RNA- and DNA-based active pharmaceutical ingredients, and will support Good Manufacturing Practice (GMP)-compliant production for large-scale projects on behalf of BioSpring’s global partners.
AI via FreepikSwedish clinical-stage pharmaceutical company Vicore Pharma has secured SEK100m, supported by existing and new investors. The injection of capital will allow the company to scale the clinical development of its portfolio of therapies in respiratory and fibrotic diseases.
CordenPharma is making a record investment of about €900m over the next three years in expanding its peptide platform, both at its Colorado, US site and in Europe.
Austrian Apeiron Biologics goes to Ligand Pharmaceuticals for US$100m.
Forbion BioEconomy represents a strategic expansion of Forbion’s investment scope in biotech and in the life sciences sector to address challenges relating to the environment, the growing need for a sustainable supply of food and the rapid depletion of natural resources.
Finnish Solar Foods Oy has started microbial production of its protein powder Solein in Factory 01, Solar Foods’ first commercial-scale production facility in Vantaa, Finland.
Basel-headquartered Roche AG has inaugurated a brand new €90m gene therapy development centre in Penzberg near Munich.
Oxford Science Enterprises (OSE), the independent investment company created to found, fund and build transformational businesses via its unique partnership with the University of Oxford, announced it has raised a further £250 million ($300 million) in funding. This brings the total amount raised by OSE to more than £850 million (>$1 billion) since inception in 2015 according to the company´s statement.
Andera Partners, Paris based European private equity player, announced on Wednesday that, together with RA Capital Management, it is leading an oversubscribed and up-sized $118m Series B financing for Mineralys Therapeutics, Inc., Philadelphia (USA), a private, clinical-stage biopharmaceutical company developing novel therapy for the treatment of hypertension.